The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Immunotherapy Drugs for Neuroblastoma Market Research Report 2024

Global Immunotherapy Drugs for Neuroblastoma Market Research Report 2024

Publishing Date : Jun, 2023

License Type :

Report Code : 1744125

No of Pages : 89

Ask Your Query

Report Description
Table of Content

Synopsis
Neuroblastoma (NB) is the most common cancer in childhood and infancy. Most children with neuroblastoma are diagnosed before age 5 and symptoms can range from a painless bump in the abdomen to fevers and limp. Neuroblastoma treatment depends on multiple factors, including the patient's age, whether the tumor has already spread beyond its initial location and the risk of the tumor growing or spreading in the future.

Global Immunotherapy Drugs for Neuroblastoma market is projected to reach US$ 63 million in 2029, increasing from US$ 45 million in 2022, with the CAGR of 4.6% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Immunotherapy Drugs for Neuroblastoma market research.

Key manufacturers engaged in the Immunotherapy Drugs for Neuroblastoma industry include United Therapeutics, Y-mAbs Therapeutics, EUSA Pharma, ANI Pharmaceuticals, Baxter Healthcare, Ingenus Pharmaceuticals, Pfizer, Hikma Pharmaceuticals and Teva Pharmaceuticals, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.

When refers to consumption region, % volume of Immunotherapy Drugs for Neuroblastoma were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Immunotherapy Drugs for Neuroblastoma market and estimated to attract more attentions from industry insiders and investors.

Report Scope

This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Immunotherapy Drugs for Neuroblastoma market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.

By Company

United Therapeutics
Y-mAbs Therapeutics
EUSA Pharma
ANI Pharmaceuticals
Baxter Healthcare
Ingenus Pharmaceuticals
Pfizer
Hikma Pharmaceuticals
Teva Pharmaceuticals

Segment by Type

Dinutuximab
Naxitamab
Other

Segment by Application

Hospital
Clinic
Other

Consumption by Region

North America (United States, Canada)
Europe (Germany, France, U.K., Italy, Russia)
Asia-Pacific (China, Japan, South Korea, India, Australia, China Taiwan, Indonesia, Thailand, Malaysia)
Latin America (Mexico, Brazil, Argentina)
Middle East & Africa (Turkey, Saudi Arabia, UAE)

The Immunotherapy Drugs for Neuroblastoma report covers below items:

Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source

Index

1 Immunotherapy Drugs for Neuroblastoma Market Overview
1.1 Product Overview and Scope of Immunotherapy Drugs for Neuroblastoma
1.2 Immunotherapy Drugs for Neuroblastoma Segment by Type
1.2.1 Global Immunotherapy Drugs for Neuroblastoma Market Value Comparison by Type (2023-2029)
1.2.2 Dinutuximab
1.2.3 Naxitamab
1.2.4 Other
1.3 Immunotherapy Drugs for Neuroblastoma Segment by Application
1.3.1 Global Immunotherapy Drugs for Neuroblastoma Market Value by Application: (2023-2029)
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Other
1.4 Global Immunotherapy Drugs for Neuroblastoma Market Size Estimates and Forecasts
1.4.1 Global Immunotherapy Drugs for Neuroblastoma Revenue 2018-2029
1.4.2 Global Immunotherapy Drugs for Neuroblastoma Sales 2018-2029
1.4.3 Global Immunotherapy Drugs for Neuroblastoma Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Immunotherapy Drugs for Neuroblastoma Market Competition by Manufacturers
2.1 Global Immunotherapy Drugs for Neuroblastoma Sales Market Share by Manufacturers (2018-2023)
2.2 Global Immunotherapy Drugs for Neuroblastoma Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Immunotherapy Drugs for Neuroblastoma Average Price by Manufacturers (2018-2023)
2.4 Global Immunotherapy Drugs for Neuroblastoma Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Immunotherapy Drugs for Neuroblastoma, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Immunotherapy Drugs for Neuroblastoma, Product Type & Application
2.7 Immunotherapy Drugs for Neuroblastoma Market Competitive Situation and Trends
2.7.1 Immunotherapy Drugs for Neuroblastoma Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Immunotherapy Drugs for Neuroblastoma Players Market Share by Revenue
2.7.3 Global Immunotherapy Drugs for Neuroblastoma Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Immunotherapy Drugs for Neuroblastoma Retrospective Market Scenario by Region
3.1 Global Immunotherapy Drugs for Neuroblastoma Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Immunotherapy Drugs for Neuroblastoma Global Immunotherapy Drugs for Neuroblastoma Sales by Region: 2018-2029
3.2.1 Global Immunotherapy Drugs for Neuroblastoma Sales by Region: 2018-2023
3.2.2 Global Immunotherapy Drugs for Neuroblastoma Sales by Region: 2024-2029
3.3 Global Immunotherapy Drugs for Neuroblastoma Global Immunotherapy Drugs for Neuroblastoma Revenue by Region: 2018-2029
3.3.1 Global Immunotherapy Drugs for Neuroblastoma Revenue by Region: 2018-2023
3.3.2 Global Immunotherapy Drugs for Neuroblastoma Revenue by Region: 2024-2029
3.4 North America Immunotherapy Drugs for Neuroblastoma Market Facts & Figures by Country
3.4.1 North America Immunotherapy Drugs for Neuroblastoma Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Immunotherapy Drugs for Neuroblastoma Sales by Country (2018-2029)
3.4.3 North America Immunotherapy Drugs for Neuroblastoma Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Immunotherapy Drugs for Neuroblastoma Market Facts & Figures by Country
3.5.1 Europe Immunotherapy Drugs for Neuroblastoma Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Immunotherapy Drugs for Neuroblastoma Sales by Country (2018-2029)
3.5.3 Europe Immunotherapy Drugs for Neuroblastoma Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Immunotherapy Drugs for Neuroblastoma Market Facts & Figures by Country
3.6.1 Asia Pacific Immunotherapy Drugs for Neuroblastoma Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Immunotherapy Drugs for Neuroblastoma Sales by Country (2018-2029)
3.6.3 Asia Pacific Immunotherapy Drugs for Neuroblastoma Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Immunotherapy Drugs for Neuroblastoma Market Facts & Figures by Country
3.7.1 Latin America Immunotherapy Drugs for Neuroblastoma Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Immunotherapy Drugs for Neuroblastoma Sales by Country (2018-2029)
3.7.3 Latin America Immunotherapy Drugs for Neuroblastoma Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Immunotherapy Drugs for Neuroblastoma Market Facts & Figures by Country
3.8.1 Middle East and Africa Immunotherapy Drugs for Neuroblastoma Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Immunotherapy Drugs for Neuroblastoma Sales by Country (2018-2029)
3.8.3 Middle East and Africa Immunotherapy Drugs for Neuroblastoma Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Immunotherapy Drugs for Neuroblastoma Sales by Type (2018-2029)
4.1.1 Global Immunotherapy Drugs for Neuroblastoma Sales by Type (2018-2023)
4.1.2 Global Immunotherapy Drugs for Neuroblastoma Sales by Type (2024-2029)
4.1.3 Global Immunotherapy Drugs for Neuroblastoma Sales Market Share by Type (2018-2029)
4.2 Global Immunotherapy Drugs for Neuroblastoma Revenue by Type (2018-2029)
4.2.1 Global Immunotherapy Drugs for Neuroblastoma Revenue by Type (2018-2023)
4.2.2 Global Immunotherapy Drugs for Neuroblastoma Revenue by Type (2024-2029)
4.2.3 Global Immunotherapy Drugs for Neuroblastoma Revenue Market Share by Type (2018-2029)
4.3 Global Immunotherapy Drugs for Neuroblastoma Price by Type (2018-2029)
5 Segment by Application
5.1 Global Immunotherapy Drugs for Neuroblastoma Sales by Application (2018-2029)
5.1.1 Global Immunotherapy Drugs for Neuroblastoma Sales by Application (2018-2023)
5.1.2 Global Immunotherapy Drugs for Neuroblastoma Sales by Application (2024-2029)
5.1.3 Global Immunotherapy Drugs for Neuroblastoma Sales Market Share by Application (2018-2029)
5.2 Global Immunotherapy Drugs for Neuroblastoma Revenue by Application (2018-2029)
5.2.1 Global Immunotherapy Drugs for Neuroblastoma Revenue by Application (2018-2023)
5.2.2 Global Immunotherapy Drugs for Neuroblastoma Revenue by Application (2024-2029)
5.2.3 Global Immunotherapy Drugs for Neuroblastoma Revenue Market Share by Application (2018-2029)
5.3 Global Immunotherapy Drugs for Neuroblastoma Price by Application (2018-2029)
6 Key Companies Profiled
6.1 United Therapeutics
6.1.1 United Therapeutics Corporation Information
6.1.2 United Therapeutics Description and Business Overview
6.1.3 United Therapeutics Immunotherapy Drugs for Neuroblastoma Sales, Revenue and Gross Margin (2018-2023)
6.1.4 United Therapeutics Immunotherapy Drugs for Neuroblastoma Product Portfolio
6.1.5 United Therapeutics Recent Developments/Updates
6.2 Y-mAbs Therapeutics
6.2.1 Y-mAbs Therapeutics Corporation Information
6.2.2 Y-mAbs Therapeutics Description and Business Overview
6.2.3 Y-mAbs Therapeutics Immunotherapy Drugs for Neuroblastoma Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Y-mAbs Therapeutics Immunotherapy Drugs for Neuroblastoma Product Portfolio
6.2.5 Y-mAbs Therapeutics Recent Developments/Updates
6.3 EUSA Pharma
6.3.1 EUSA Pharma Corporation Information
6.3.2 EUSA Pharma Description and Business Overview
6.3.3 EUSA Pharma Immunotherapy Drugs for Neuroblastoma Sales, Revenue and Gross Margin (2018-2023)
6.3.4 EUSA Pharma Immunotherapy Drugs for Neuroblastoma Product Portfolio
6.3.5 EUSA Pharma Recent Developments/Updates
6.4 ANI Pharmaceuticals
6.4.1 ANI Pharmaceuticals Corporation Information
6.4.2 ANI Pharmaceuticals Description and Business Overview
6.4.3 ANI Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Sales, Revenue and Gross Margin (2018-2023)
6.4.4 ANI Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Product Portfolio
6.4.5 ANI Pharmaceuticals Recent Developments/Updates
6.5 Baxter Healthcare
6.5.1 Baxter Healthcare Corporation Information
6.5.2 Baxter Healthcare Description and Business Overview
6.5.3 Baxter Healthcare Immunotherapy Drugs for Neuroblastoma Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Baxter Healthcare Immunotherapy Drugs for Neuroblastoma Product Portfolio
6.5.5 Baxter Healthcare Recent Developments/Updates
6.6 Ingenus Pharmaceuticals
6.6.1 Ingenus Pharmaceuticals Corporation Information
6.6.2 Ingenus Pharmaceuticals Description and Business Overview
6.6.3 Ingenus Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Ingenus Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Product Portfolio
6.6.5 Ingenus Pharmaceuticals Recent Developments/Updates
6.7 Pfizer
6.6.1 Pfizer Corporation Information
6.6.2 Pfizer Description and Business Overview
6.6.3 Pfizer Immunotherapy Drugs for Neuroblastoma Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Pfizer Immunotherapy Drugs for Neuroblastoma Product Portfolio
6.7.5 Pfizer Recent Developments/Updates
6.8 Hikma Pharmaceuticals
6.8.1 Hikma Pharmaceuticals Corporation Information
6.8.2 Hikma Pharmaceuticals Description and Business Overview
6.8.3 Hikma Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Hikma Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Product Portfolio
6.8.5 Hikma Pharmaceuticals Recent Developments/Updates
6.9 Teva Pharmaceuticals
6.9.1 Teva Pharmaceuticals Corporation Information
6.9.2 Teva Pharmaceuticals Description and Business Overview
6.9.3 Teva Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Teva Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Product Portfolio
6.9.5 Teva Pharmaceuticals Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Immunotherapy Drugs for Neuroblastoma Industry Chain Analysis
7.2 Immunotherapy Drugs for Neuroblastoma Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Immunotherapy Drugs for Neuroblastoma Production Mode & Process
7.4 Immunotherapy Drugs for Neuroblastoma Sales and Marketing
7.4.1 Immunotherapy Drugs for Neuroblastoma Sales Channels
7.4.2 Immunotherapy Drugs for Neuroblastoma Distributors
7.5 Immunotherapy Drugs for Neuroblastoma Customers
8 Immunotherapy Drugs for Neuroblastoma Market Dynamics
8.1 Immunotherapy Drugs for Neuroblastoma Industry Trends
8.2 Immunotherapy Drugs for Neuroblastoma Market Drivers
8.3 Immunotherapy Drugs for Neuroblastoma Market Challenges
8.4 Immunotherapy Drugs for Neuroblastoma Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Published By : QY Research

Why ‘The Market Reports’

In Business:

Since 2015

Pre Sales Support:

24*7

Post Sales Support:

24*7

Turn Around Time:

Usually 2 Hours

Clients Served:

425 and counting

Clients Assisted:

1750 and counting

Client Types:

Govt Projects, Private Companies, Consultant and Individuals

Payment:

Partners with:

Number of reports:

1,000,000 and counting

Custom Research:

Available

Report Availability:

Global and Regional Reports

Report Delivery Format:

Usually PDF

Security:

Latest Life Science Market Reports

Global Medical Coatings Market - Industry Trends and Forecast to 2031

Global Pediatric MRI Systems Market Research Report 2024

Global Oridonin Market Research Report 2024

Global Dual Fetal Monitors Market Research Report 2024

Global Animal Examination Otoscopes Market Research Report 2024

Payments Accepted From

Connect with us at

Complete Secure Website

#socialicons>a span { top: 0px; left: -100%; -webkit-transition: all 0.3s ease; -moz-transition: all 0.3s ease-in-out; -o-transition: all 0.3s ease-in-out; -ms-transition: all 0.3s ease-in-out; transition: all 0.3s ease-in-out;} #socialicons>ahover div{left: 0px;}